New Drugs 2018
Dr. Ranjan Kumar Patel
New Drug Mechanism of Action Use
Lutathera Radiolabeled somatostatin Somatostatin receptor
analog positive
gastroenteropancreatic
neuroendocrine tumors
Bictegravir Integrase inhibitor HIV
Apalutamide Androgen receptor antagonist Prostate cancer
Tezacaftor + Tezacaftor is a corrector and Cystic fibrosis in patients aged
Ivacaftor ivacaftor is a potentiator of 12 years and older who are
cystic fibrosis transmembrane homozygous for the F508del
regulator mutation or who have at least
one mutation in the cystic
fibrosis transmembrane
conductance regulator (CFTR)
gene that is responsive to
tezacaftor/ivacaftor based on
in vitro data and/or clinical
evidence
Ibalizumab Anti CD-4 receptor monoclonal Multidrug resistant HIV
antibody
Tildrakizumab Anti IL-23 monoclonal Ab Plaque psoriasis
Burosumab Anti Fibroblast growth factor 23 X linked hypophosphatemia
(KRN23) blocking antibody
75 Hours of Online Pharmacology Videos at [Link]
New Drugs 2018
Dr. Ranjan Kumar Patel
Fostamatinib Spleen tyrosine kinase inhibitor Immune thrombocytopenic
purpura
Tolvaptan V2 receptor inhibition Autosomal dominant
decreases cyclic AMP which polycystic kidney disease
results in decreased water
secretion and proliferation of
cells, resulting in decreased
growth of cysts
Erenumab Anti CGRP-receptor monoclonal Prophylaxis of migraine by
antibody subcutaneous route 70/140
mg once monthly
Avatrombopag oral thrombopoietin receptor Thrombocytopenia in patients
Lusutrombopag agonist with chronic liver disease,
prior to any procedure
Lokelma (sodium Highly-selective, oral Hyperkalemia
zirconium potassium-removing agent
cyclosilicate preferentially captures
potassium in exchange for
hydrogen and sodium and
increases fecal potassium
excretion
Pegvaliase Phenylalanine-metabolizing Phenylketonuria who have
enzyme uncontrolled blood
phenylalanine concentrations
greater than 600 micromol/L
on existing management
75 Hours of Online Pharmacology Videos at [Link]
New Drugs 2018
Dr. Ranjan Kumar Patel
Lofexidine Central alpha-2 agonist To decrease withdrawal
symptoms in opioid
dependence
Andexanet alfa Recombinant protein that is a To reverse anticoagulant
modified form of factor Xa effect of factor Xa inhibitors
Baricitinib Janus Kinase 1 and 2 inhibitor Rheumatoid arthritis not
responding to TNF alpha
inhibitors
Moxidectin Stimulates glutamate sensitive O. volvulus
chloride channels, which leads
to flaccid paralysis in helminths
Cannabidiol Unknown LGS or Dravet syndrome in
children more than 2 years of
age
Plazomicin Aminoglycoside Complicated UTI including
pyelonephritis caused by gram
negative organisms
Binimetinib MEK 1/2 inhibitor Unresectable or metastatic
melanoma which is positive
for BRAF V600E or V600K
mutation
75 Hours of Online Pharmacology Videos at [Link]
New Drugs 2018
Dr. Ranjan Kumar Patel
Encorafenib BRAF inhibitor Used along with binimetinib
for condition mentioned
above
Tecovirimat Inhibits orthopoxvirus VP37 Smallpox
envelope wrapping protein
Ivosidenib Inhibitor of mutant Isocitrate Relapsed or refractory AML
Dehydrogenase 1 (IDH1) positive for Isocitrate
Dehydrogenase 1 (IDH1)
mutation
Tafenoquine Hypnozoite cidal drug Radical cure of malaria caused
by P. vivax
Elagolix GnRH receptor antagonist Endometriosis associated pain
Mogamulizumab Anti CCR4 receptor antibody Relapsed or refractory mycosis
fungoides or Sezary syndrome
Patisiran It is double stranded SiRNA Hereditary transthyretin
which degrades mutant and mediated amyloidosis
wild type transthyretin (TTR) associated polyneuropathy
mRNA and decreases
deposition of transthyretin in
tissues
Migalastat Pharmacological chaperone Fabry disease
that binds to active site of alpha
galactosidase A and facilitates
75 Hours of Online Pharmacology Videos at [Link]
New Drugs 2018
Dr. Ranjan Kumar Patel
its transfer from endoplasmic
reticulum to lysosomes
Stiripentol Acts via inhibitory As an add on to clobazam for
neurotransmitter GABA treatment of LGS or Dravet
syndrome
Cenegermin Recombinant human nerve Neurotrophic keratitis
(bkbj) growth factor
Lanadelumab Anti kallikrein monoclonal Prophylaxis of hereditary
antibody angioedema
Eravacycline Tetracycline Complicated abdominal
infections
Doravirine Non Nucleoside Reverse HIV
Transcriptase Inhibitor (NNRTI)
Moxetumomab- Immunotoxin made up of anti Relapsed or refractory hairy
Pasudotox CD-22 monoclonal antibody and cell leukemia with prior 2
pseudomonas exotoxin, PE38 systemic therapy failure
including purine analogs
Fremanuzumab Anti CGRP ligand monoclonal Prophylaxis of migraine
Galcenezumab antibodies
Duvelisib Dual inhibitor of Relapsed or refractory CLL and
phosphatidylinositol-3 kinases SLL
(PI3K) delta and gamma
Cemiplimab Anti PD-1 antibody Metastatic or advanced
cutaneous squamous cell
75 Hours of Online Pharmacology Videos at [Link]
New Drugs 2018
Dr. Ranjan Kumar Patel
carcinoma, that can not be
treated by surgery or radiation
Sarecycline Tetracycline antibiotic Inflammatory non nodular
acne in age group > 9 years
Omadacycline Tetracycline antibiotic Community acquired
pneumonia and acute
bacterial skin infection
Dacomitinib EGFR tyrosine kinase inhibitor Non small cell cancer of lungs
Elapegademase Recombinant adenosine Adenosine deaminase severe
deaminase enzyme combined immune deficiency
(ADA-SCID)
Baloxavir Inhibits viral replication by Acute uncomplicated
marboxil inhibiting endonuclease activity influenza
of polymerase acidic protein
(present in viral RNA
polymerase complex) required
for viral gene transcription
Rifamycin RNA polymerase inhibitor Traveler’s diarrhoea caused by
E. coli
Inotersen Antisense oligonueotide that Polyneuropathy of hereditary
degrades wild and mutant type transthyretin mediated
TTR mRNA and decreases TTR amyloidosis
protein deposits in tissues
Emapalumab Anti-interferon gamma Primary hemophagocytic
monoclonal antibody lymphohistiocytosis (HLH)
Revefenacin Long acting anticholinergic (M3 COPD
antagonist)
75 Hours of Online Pharmacology Videos at [Link]
New Drugs 2018
Dr. Ranjan Kumar Patel
Sufentanil Opioid agonist Acute pain not responding to
other drugs
Talazoparib Poly ADP ribose polymerase BRCA mutated HER2 negative
(PARP) inhibitor breast cancer
Lorlatinib ALK/ROS1 tyrosine kinase Non small cell lung cancer
inhibitor resistant to other drugs in this
class like alectinib or Ceritinib
Glasdegib Hedgehog pathway inhibitor AML along with cytarabine in
patients > 75 years or in
patients with comorbidities
that are contraindication for
intensive induction
chemotherapy
75 Hours of Online Pharmacology Videos at [Link]
